Novo, GlaxoSmithKline and Merck-backed molecular profiling platform HTG offered almost 3.6 million shares priced at $14 each.

HTG Molecular Diagnostics, a US-based molecular platform profiling provider backed by pharmaceutical companies Novo, GlaxoSmithKline (GSK) and Merck, has raised $50m in an initial public offering on Nasdaq.

The company offered 3.57 million shares priced at $14 each, in the middle of the IPO’s $13 to $15 range.

Founded in 2000, HTG’s profiling platform, HTG Edge, provides automated sequencing of tumours, requiring significantly smaller samples to do so than other technologies. The platform also combines several profiling techniques, eliminating the…